MedImmune's Restructured Oncology Unit Displays Its Fruits At AACR

MedImmune's R&D reorganization into therapeutic business units takes the start-to-finish, integrated approach that has become trendy with big pharmas trying to capture the innovative spirit of small biotech – and the oncology pipeline will be a key test of how that restructuring delivers.